ES2116415T3 - Metodo para tratar la enfermedad de crohn, la colitis ulcerosa o la proctitis ulcerosa. - Google Patents

Metodo para tratar la enfermedad de crohn, la colitis ulcerosa o la proctitis ulcerosa.

Info

Publication number
ES2116415T3
ES2116415T3 ES93306248T ES93306248T ES2116415T3 ES 2116415 T3 ES2116415 T3 ES 2116415T3 ES 93306248 T ES93306248 T ES 93306248T ES 93306248 T ES93306248 T ES 93306248T ES 2116415 T3 ES2116415 T3 ES 2116415T3
Authority
ES
Spain
Prior art keywords
ulcerous
disease
proctitis
colitis
treating crohn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93306248T
Other languages
English (en)
Inventor
Craig Eugene Caufield
John Henry Musser
Surendra Nath Sehgal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Application granted granted Critical
Publication of ES2116415T3 publication Critical patent/ES2116415T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Abstract

ESTA INVENCION SE REFIERE A UN METODO PARA TRATAR LA COLITIS ULCEROSA, LA ENFERMEDAD DE CROHN O LA PROCTITIS ULCEROSA EN UN MAMIFERO NECESITADO DE ESTE QUE CONSISTE EN LA ADMINISTRACION DE UNA CANTIDAD EFECTIVA DE RAPAMICINA, SOLA O EN COMBINACION CON CICLOSPORINA A.
ES93306248T 1992-08-17 1993-08-06 Metodo para tratar la enfermedad de crohn, la colitis ulcerosa o la proctitis ulcerosa. Expired - Lifetime ES2116415T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/931,243 US5286731A (en) 1991-09-17 1992-08-17 Method of treating immunoinflammatory bowel disease

Publications (1)

Publication Number Publication Date
ES2116415T3 true ES2116415T3 (es) 1998-07-16

Family

ID=25460461

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93306248T Expired - Lifetime ES2116415T3 (es) 1992-08-17 1993-08-06 Metodo para tratar la enfermedad de crohn, la colitis ulcerosa o la proctitis ulcerosa.

Country Status (13)

Country Link
US (1) US5286731A (es)
EP (1) EP0583925B1 (es)
JP (1) JP2637682B2 (es)
KR (1) KR100299395B1 (es)
AT (1) ATE166786T1 (es)
AU (1) AU677011B2 (es)
CA (1) CA2104042A1 (es)
DE (1) DE69318902T2 (es)
DK (1) DK0583925T3 (es)
ES (1) ES2116415T3 (es)
GR (1) GR3027610T3 (es)
HK (1) HK1009641A1 (es)
SG (1) SG47786A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434260A (en) * 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5489680A (en) * 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5480988A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US6204243B1 (en) 1993-09-01 2001-03-20 Novatis Ag Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
US5389639A (en) * 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5525610A (en) * 1994-03-31 1996-06-11 American Home Products Corporation 42-Epi-rapamycin and pharmaceutical compositions thereof
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5463048A (en) * 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5561138A (en) * 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) * 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
US20040018236A1 (en) * 1995-05-08 2004-01-29 Robert Gurny Nanoparticles for oral administration of pharmaceutical agents of low solubility
ES2182112T3 (es) 1996-07-30 2003-03-01 Novartis Ag Composiciones farmaceuticas para el tratamiento del rechazo de transplantes y de estados autoinmunes o inflamatorios, que comprenden ciclosporina a y 40-o-(2-hidroxietil)-rapamicina.
IT1289815B1 (it) * 1996-12-30 1998-10-16 Sorin Biomedica Cardio Spa Stent per angioplastica e relativo procedimento di produzione
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
EP1319008B1 (en) 2000-09-19 2008-10-15 Wyeth Water soluble rapamycin esters
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
US8263582B2 (en) * 2001-03-15 2012-09-11 Soligenix, Inc. Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
ZA200603888B (en) * 2001-06-01 2007-05-30 Wyeth Corp Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
CA2455311A1 (en) 2001-08-22 2003-03-06 Wyeth Rapamycin dialdehydes
CA2455308A1 (en) 2001-08-22 2003-03-06 Wyeth Rapamycin 29-enols
US20040137066A1 (en) * 2001-11-26 2004-07-15 Swaminathan Jayaraman Rationally designed therapeutic intravascular implant coating
US6641611B2 (en) 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
CN100522967C (zh) 2002-02-01 2009-08-05 阿里亚德基因治疗公司 含磷化合物及其应用
RU2344821C2 (ru) 2002-07-30 2009-01-27 Уайт Парентеральные композиции, содержащие гидроксиэфиры рапамицина
CN100415233C (zh) * 2002-09-17 2008-09-03 惠氏公司 口服制剂
AR042938A1 (es) * 2003-02-06 2005-07-06 Wyeth Corp Uso del cci-779 en el tratamiento de la fibrosis hepatica
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
BRPI0409632A (pt) * 2003-04-22 2006-04-25 Wyeth Corp combinações antineoplásticas
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US7151085B2 (en) * 2004-11-15 2006-12-19 Allergan, Inc. Therapeutic methods using cyclosporine components
US7135455B2 (en) * 2004-11-15 2006-11-14 Allergan, Inc Methods for the therapeutic use of cyclosporine components
CN101360495B (zh) 2005-11-14 2012-03-14 阿里亚德医药股份有限公司 对癌症病人给药mTOR抑制剂
RU2010104916A (ru) * 2006-08-16 2011-08-20 Михаил В. Благосклонный (US) Способ профилактики и лечения возрастных заболеваний
US7867988B2 (en) 2006-09-13 2011-01-11 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
BRPI0919794A2 (pt) * 2008-10-03 2015-12-15 Elixir Medical Corp dispositivo para uso intracorpóreo, e, composto
CA2937492C (en) 2008-11-11 2019-08-13 The Board Of Regents Of The University Of Texas System Inhibition of mammalian target of rapamycin
EA023244B1 (ru) * 2009-04-10 2016-05-31 Хаян Ки Способ предотвращения старения клеток
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US20110150856A1 (en) * 2009-12-21 2011-06-23 Sarah Bacus Compositions and methods for treatment of vitiligo
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
ES2900426T3 (es) 2013-12-31 2022-03-16 Rapamycin Holdings Llc Preparaciones orales y uso de nanopartículas de rapamicina
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
PH26083A (en) * 1987-11-09 1992-02-06 Sandoz Ltd 11, 28-dioxa-4-azatricyclo [22.3.1.04.9) octacos-18-ene derivatives and pharmaceutical compositions containing them and method of use thereof
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5023264A (en) * 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
US5023263A (en) * 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
DE69129459T2 (de) * 1990-08-10 1998-10-15 Anormed Inc Immunosuppressive zusammensetzungen
US5080899A (en) * 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5091389A (en) * 1991-04-23 1992-02-25 Merck & Co., Inc. Lipophilic macrolide useful as an immunosuppressant
US5102876A (en) * 1991-05-07 1992-04-07 American Home Products Corporation Reduction products of rapamycin
US5138051A (en) * 1991-08-07 1992-08-11 American Home Products Corporation Rapamycin analogs as immunosuppressants and antifungals
US5286730A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease

Also Published As

Publication number Publication date
GR3027610T3 (en) 1998-11-30
EP0583925A1 (en) 1994-02-23
DE69318902T2 (de) 1999-02-25
JP2637682B2 (ja) 1997-08-06
DK0583925T3 (da) 1998-10-12
US5286731A (en) 1994-02-15
HK1009641A1 (en) 1999-06-04
AU4465493A (en) 1994-02-24
JPH06183967A (ja) 1994-07-05
AU677011B2 (en) 1997-04-10
ATE166786T1 (de) 1998-06-15
CA2104042A1 (en) 1994-02-18
EP0583925B1 (en) 1998-06-03
KR940003555A (ko) 1994-03-12
SG47786A1 (en) 1998-04-17
KR100299395B1 (ko) 2001-10-22
DE69318902D1 (de) 1998-07-09

Similar Documents

Publication Publication Date Title
ES2116415T3 (es) Metodo para tratar la enfermedad de crohn, la colitis ulcerosa o la proctitis ulcerosa.
GR3034479T3 (en) Method of treating hyperproliferative vascular disease using rapamycin, eventually in combination with mycophenolic acid.
ATE135226T1 (de) Zusammensetzung enthaltend heparin und rapamycin
FR2711957B1 (fr) Procédé et dispositif d'assemblage pour pièces de carrosserie.
GR3019792T3 (en) Use of rapamycin and derivatives and prodrugs thereof in the manufacture of a medicament for inhibiting transplant rejection in mammals
DK0691130T3 (da) Anvendelse af rapamycin til fremstilling af et lægemiddel til forebyggelse og behandling af hyperproliferative vaskulære sygdomme, eventuelt i kombination med mycophenolsyre
FR2714629B1 (fr) Procédé et dispositif d'ébavurage de pièces mécaniques.
KR910019620A (ko) 15-케토-프로스타글란딘 화합물을 사용한 췌장 질병의 치료
GR3020310T3 (en) 29-Demethoxyrapamycin for inducing immunosuppression
MX9303084A (es) Agentes fungicidas de 1-aril-3-(3,4-dihidro-4-oxo-3-quinazolinil) urea y composicion que los comprende.
EA199800816A1 (ru) Способы лечения и профилактики интерстициального цистита
FI940519A0 (fi) Interleukiini-10-analogien tai -antagonistien käyttö endotoksiinin taisuperantigeenin indusoiman toksisuuden hoitamiseksi
FR2695335B1 (fr) Tiroir linéaire de poche à acier.
FI903775A0 (fi) Foerfarande foer behandling av skinn och de erhaollna skinnen.
FR2658281B1 (fr) Lanceur a rails pour l'acceleration electromagnetique de projectiles de forme allongee.
FR2719798B1 (fr) Dispositif d'usinage de pièces symétriques.
JPS57501527A (es)
ITRM930519A0 (it) Agente che favorisce la capacita' di vegetazione o di rivegetazione interreni inorganici spogli procedimento cherapplica detto agente.
FR2702834B1 (fr) Procédé et dispositif optiques de détermination d'orientations de pièces.
FR2707509B3 (fr) Dispositif d'immobilisation de cages de buts amovibles.
ITRM910449A0 (it) Procedimento per conformare e/o proteggere l'interno di un corpo cavo,e mezzi per la realizzazione di detto procedimento.
RU93056862A (ru) Способ предотвращения рестеноза или снижения его степени
BR9100266A (pt) Componente extrator de liquido e corpo fibroso

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 583925

Country of ref document: ES